Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Carboplatin Generic Name & Formulations
Legal Class
Rx
General Description
Carboplatin 10mg/mL; soln for IV infusion.
Pharmacological Class
Platinum coordination complex.
How Supplied
Contact supplier.
Manufacturer
Carboplatin Indications
Indications
Initial treatment of advanced ovarian cancer in combination with other chemotherapy. Secondary treatment of recurrent ovarian cancer after prior chemotherapy, including patients previously treated with cisplatin.
Carboplatin Dosage and Administration
Adult
See literature. Give by IV infusion over ≥15 minutes. Combination therapy with cyclophosphamide (previously untreated): 300mg/m2 on Day 1 every 4 weeks for 6 cycles. As a single agent for recurrent ovarian carcinoma: 360mg/m2 on Day 1 every 4 weeks. In either case the Calvert equation may be used (Total Dose [mg]=[target area under the curve (AUC)] X [glomerular filtration rate + 25]). Use Calvert equation for elderly patients. Adjust dose for renal insufficiency and blood counts (see literature).
Children
Not recommended.
Carboplatin Contraindications
Contraindications
Severe bone marrow suppression. Significant bleeding. Pregnancy (Cat.D). Nursing mothers.
Carboplatin Boxed Warnings
Not Applicable
Carboplatin Warnings/Precautions
Warnings/Precautions
Dose-related bone marrow suppression. Elderly. Renal dysfunction. Monitor blood counts frequently; do not repeat dose until neutrophil count is >2,000 and platelets are >100,000. Anemia (transfusions may be needed). Premedicate with antiemetics; increasing infusion time or dividing total daily dose over 5 days may reduce emesis. Previous platinum-containing therapy. Loss of vision with higher than recommended doses.
Carboplatin Pharmacokinetics
See Literature
Carboplatin Interactions
Interactions
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). Caution with other myelosuppressives.
Carboplatin Adverse Reactions
Adverse Reactions
Bone marrow suppression with possible infectious or hemorrhagic complications, anemia, vomiting, abdominal pain, anorexia, diarrhea, constipation, peripheral neuropathies, ototoxicity, visual disturbances, taste perversion, CNS symptoms, nephrotoxicity, hepatotoxicity, electrolyte changes, hypersensitivity reactions, injection site reactions, pain, asthenia, alopecia, malaise, hypertension; respiratory, genitourinary, mucosal, cardiovascular events; rare: hemolytic uremic syndrome.
Carboplatin Clinical Trials
See Literature
Carboplatin Note
Notes
Avoid contact with aluminum (eg, needles). Formerly known under the brand name Paraplatin.
Carboplatin Patient Counseling
See Literature
